A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-Small-Cell lung cancer

Annals of Oncology

Volumn 24, Issue 10, 2013, Pages 2601-2606

  Kelly, R J ^a   Thomas, A ^b   Rajan, A ^b   Chun, G ^b   Lopez Chavez, A ^b   Szabo, E ^b   Spencer, S ^b   Carter, C A ^c   Guha, U ^b   Khozin, S ^b   Poondru, S ^d   Van Sant, C ^d   Keating, A ^d   Steinberg, S M ^b   Figg, W ^b   Giaccone, G ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Apoptosis; Non Small Cell lung cancer; Sepantronium bromide; Survivin

Indexed keywords

CARBOPLATIN; PACLITAXEL; SEPANTRONIUM BROMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERURICEMIA; HYPOKALEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; VOMITING;

APOPTOSIS; NON-SMALL-CELL LUNG CANCER; SEPANTRONIUM BROMIDE; SURVIVIN;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAPHTHOQUINONES; PACLITAXEL; SURVIVAL; TREATMENT OUTCOME;

EID: 84884717482     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt249     Document Type: Article

References (22)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
2. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3(1): 46-54.
3. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8(1): 61-70.
4. Li F, Ambrosini G, Chu EY et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396(6711): 580-584.
5. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007; 12(9): 1543-1568.
6. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004; 64(20): 7183-7190.
7. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3(8): 917-921.
8. Blanc-Brude OP, Mesri M, Wall NR et al. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003; 9(7): 2683-2692.
9. Kawasaki H, Altieri DC, Lu CD et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58(22): 5071-5074.
10. Span PN, Sweep FC, Wiegerinck ET et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 2004; 50(11): 1986-1993.
11. Vischioni B, van der Valk P, Span SW et al. Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol 2004; 15(11): 1654-1660.
12. Nakahara T, Kita A, Yamanaka K et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67(17): 8014-8021.
13. Nakamura N, Yamauchi T, Hiramoto M et al. Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin. Mol Cell Proteomics 2012; 11(7): M111.013243.
14. Yamauchi T, Nakamura N, Hiramoto M et al. Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochem Biophys Res Commun 2012; 425(4): 711-716.
15. Tolcher AW, Mita A, Lewis LD et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008; 26(32): 5198-5203.
16. Satoh T, Okamoto I, Miyazaki M et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009; 15 (11): 3872-3880.
17. Giaccone G, Zatloukal P, Roubec J et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, nonsmall- cell lung cancer. J Clin Oncol 2009; 27(27): 4481-4486.
18. Iwasa T, Okamoto I, Takezawa K et al. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer 2010; 103(1): 36-42.
19. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228-247.
20. Gabrielsson J. Pharmacokinetic/pharmacodynamic data analysis: concepts and applications. pp. 9-40, 107-114. Stockholm, Sweden: Swedish Pharmaceutical Press, 1994.
21. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science 1998; 281(5375): 363. 365.
22. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346(2): 92-98.